Synovial Fluid Bank From Arthritic Patients
Launched by GILLES BOIRE · Aug 3, 2007
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
**Trial Summary: Synovial Fluid Bank From Arthritic Patients**
This clinical trial is focused on collecting a special fluid from the joints of patients with arthritis, known as synovial fluid (SF), along with blood samples. The main goal is to study new markers that could help doctors diagnose and predict the progression of arthritis. Researchers want to see how these markers change before and after treatment, which could lead to better ways to manage arthritis symptoms and improve patient care.
If you are an adult with significant swelling in your joints (called joint effusion), you might be eligible to participate in this study. However, if your swelling is due to bleeding, injury, or if you can’t provide at least 3 milliliters of fluid, you may not qualify. Participants will have the opportunity to contribute to important research that could help others with arthritis in the future. Additionally, your involvement will help scientists understand how treatments affect the biomarkers being studied. If you’re interested, the study is currently recruiting participants of all genders and ages.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Significant joint effusion
- Exclusion Criteria:
- • Hemorrhagic effusion
- • Traumatic effusion
- • Less than 3 ml total of collected fluid (used for routine analysis and culture)
- • Inability or refusal to consent
About Gilles Boire
Gilles Boire is a dedicated clinical trial sponsor committed to advancing medical research and enhancing patient care through innovative clinical studies. With a focus on delivering high-quality, evidence-based solutions, Gilles Boire collaborates with a diverse range of stakeholders, including healthcare professionals, research institutions, and regulatory bodies. The organization prioritizes patient safety and ethical standards while striving to accelerate the development of new therapies across various therapeutic areas. Through its rigorous methodologies and commitment to transparency, Gilles Boire aims to contribute significantly to the scientific community and improve health outcomes globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sherbrooke, Quebec, Canada
Patients applied
Trial Officials
Gilles Boire, MD, MSc
Principal Investigator
CHUS and Université de Sherbrooke
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials